The primary constraint on AI in clinical trials is organizational uncertainty, not regulatory objections
The real barrier to AI in clinical trials is not regulators. It’s internal uncertainty.
As artificial intelligence becomes more embedded in drug development, many sponsors and CROs continue to move cautiously. That hesitation is often attributed to regulatory resistance. But signals from regulators tell a more nuanced story.
The FDA and EMA are focused on responsible use: fit-for-purpose application, transparency, auditability, human accountability and patient protection. Rather than prohibiting AI, regulators are outlining expectations for how it should be governed, validated and used within a defined context.
That distinction matters. If the regulatory signals are openness with appropriate safeguards, then the biggest barrier is internal: fragmented interpretation, audit anxiety and organizational risk aversion that slows adoption before meaningful value is realized.
This is especially important as real-time clinical trial models gain attention. Continuous data review, earlier signal detection and adaptive oversight require governance that supports both speed and control. AI can help accelerate data flow and surface insights sooner, but decisions must remain human-led, explainable and anchored in evidence.
For organizations working in clinical trial, the opportunity is not to ask whether AI is allowed – it is to ask whether AI is being applied responsibly, with clear controls, transparent data provenance and accountability built into the operating model. When risk is managed with evidence rather than amplified by fear, AI can support smarter trial execution and stronger oversight.
Read the full article to explore why organizational uncertainty—not regulatory objection—may be the primary constraint on AI adoption in clinical trials.
Discover more about Fortrea Intelligent Technology™ and how responsible AI can help clinical development teams move with greater confidence, clarity and control.